

## PRESS RELEASE

Stockholm, 11 September 2015



### **The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme**

The annual general meeting of [Swedish Orphan Biovitrum AB](#) (publ) on 30 June 2015 resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the annual general meeting – on a directed share issue of no more than 1,036,856 redeemable- and convertible class C shares.

The general meeting also resolved to authorise the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the annual general meeting in 2016 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 11 September – 27 September 2015.

The company currently holds 2,763,768 own common shares and 396,180 own class C shares. Subsequently to the effected repurchase of class C shares above, the number of own class C shares will amount to 1,433,036.

The class C shares will, following the repurchase, be converted to common shares in the number that is required to ensure delivery under the incentive programme.

---

#### **About Sobi**

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at [www.sobi.com](http://www.sobi.com).

#### **For more information please contact**

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

[oskar.bosson@sobi.com](mailto:oskar.bosson@sobi.com)

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

[jorgen.winroth@sobi.com](mailto:jorgen.winroth@sobi.com)

*The information was released for public distribution on 11 September 2015 at 08:30 CET.*

**Swedish Orphan Biovitrum AB**

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 8 697 20 00 Fax +46 8 697 20 00 [www.sobi.com](http://www.sobi.com)